[{"orgOrder":0,"company":"SGS Life Sciences","sponsor":"Biophytis","pharmaFlowCategory":"D","therapeuticArea":"Pulmonary\/Respiratory Diseases","country":"SWITZERLAND","productType":"Small molecule","year":"2020","type":"Partnership","leadProduct":"Sarconeos","moa":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase II\/ Phase III","graph3":"SGS Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Respiratory Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"SGS Life Sciences \/ Biophytis","highestDevelopmentStatusID":"9","companyTruncated":"SGS Life Sciences \/ Biophytis"},{"orgOrder":0,"company":"SGS Life Sciences","sponsor":"Biophytis","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"FRANCE","productType":"Small molecule","year":"2020","type":"Not Applicable","leadProduct":"Sarconeos","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II\/ Phase III","graph3":"SGS Life Sciences","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"SGS Life Sciences \/ SGS","highestDevelopmentStatusID":"9","companyTruncated":"SGS Life Sciences \/ SGS"},{"orgOrder":0,"company":"SGS Life Sciences","sponsor":"Intract Pharma","pharmaFlowCategory":"D","therapeuticArea":"Gastroenterology","country":"UNITED KINGDOM","productType":"Large molecule","year":"2022","type":"Collaboration","leadProduct":"Infliximab","moa":"","graph1":"Gastroenterology","graph2":"Preclinical","graph3":"SGS Life Sciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Gastroenterology","amount2New":0,"dosageForm":"Capsule","sponsorNew":"SGS Life Sciences \/ SGS Life Sciences","highestDevelopmentStatusID":"4","companyTruncated":"SGS Life Sciences \/ SGS Life Sciences"}]

Find Clinical Drug Pipeline Developments & Deals by SGS Life Sciences

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : Formulating infliximab as an oral capsule – which must survive the digestive system's harsh environment and reach the colon intact – is transformational.

                          Brand Name : Undisclosed

                          Molecule Type : Large molecule

                          Upfront Cash : Undisclosed

                          July 18, 2022

                          Lead Product(s) : Infliximab

                          Therapeutic Area : Gastroenterology

                          Highest Development Status : Preclinical

                          Recipient : Intract Pharma

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          02

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : French biotech firm Biophytis will assess its Sarconeos (BIO101) drug as a treatment for respiratory failure caused by Covid-19 after partnering with contract research organisation (CRO) SGS.

                          Brand Name : BIO101

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 08, 2020

                          Lead Product(s) : 20-Hydroxyecdysone

                          Therapeutic Area : Pulmonary/Respiratory Diseases

                          Highest Development Status : Phase II/ Phase III

                          Sponsor : Biophytis

                          Deal Size : Undisclosed

                          Deal Type : Partnership

                          blank

                          03

                          Pharma, Lab & Chemical Expo
                          Not Confirmed
                          Pharma, Lab & Chemical Expo
                          Not Confirmed

                          Details : This pivotal, international clinical trial will be conducted in two parts, the first of which has the objective to assess treatment safety and provide an indication of activity of Sarconeos, in 50 hospitalized COVID-19 patients suffering from acute respi...

                          Brand Name : BIO101

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          July 01, 2020

                          Lead Product(s) : 20-Hydroxyecdysone

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II/ Phase III

                          Recipient : Biophytis

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank